MIRA Key Statistics, Chart & Performance
The current stock price of MIRA is 1.4 USD. In the past month the price decreased by -16.17%. In the past year, price increased by 17.65%.
MIRA Latest News, Press Relases and Analysis
MIRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.11 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 19.78 | 494.73B | ||
| MRK | MERCK & CO. INC. | 11.56 | 252.74B | ||
| PFE | PFIZER INC | 7.9 | 143.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.12B | ||
| ZTS | ZOETIS INC | 20.07 | 56.08B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.71 | 23.03B | ||
| VTRS | VIATRIS INC | 4.59 | 12.32B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.56 | 11.24B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.66 | 8.39B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.51B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.37B |
Related stock screener links
About MIRA
Company Profile
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Company Info
MIRA PHARMACEUTICALS INC
1200 Brickell Avenue, Suite 1950 #1183
Miami FLORIDA US
Employees: 3
Phone: 18133695150
MIRA PHARMACEUTICALS INC / MIRA FAQ
What does MIRA PHARMACEUTICALS INC do?
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
What is the current price of MIRA stock?
The current stock price of MIRA is 1.4 USD. The price decreased by -5.41% in the last trading session.
Does MIRA stock pay dividends?
MIRA does not pay a dividend.
How is the ChartMill rating for MIRA PHARMACEUTICALS INC?
MIRA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists MIRA stock?
MIRA stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of MIRA PHARMACEUTICALS INC (MIRA)?
MIRA PHARMACEUTICALS INC (MIRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
Who owns MIRA PHARMACEUTICALS INC?
You can find the ownership structure of MIRA PHARMACEUTICALS INC (MIRA) on the Ownership tab.
MIRA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MIRA. When comparing the yearly performance of all stocks, MIRA is one of the better performing stocks in the market, outperforming 73.9% of all stocks.
MIRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MIRA. No worries on liquidiy or solvency for MIRA as it has an excellent financial health rating, but there are worries on the profitability.
MIRA Financial Highlights
Over the last trailing twelve months MIRA reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -108.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -372.26% | ||
| ROE | -376.4% | ||
| Debt/Equity | 0 |
MIRA Forecast & Estimates
7 analysts have analysed MIRA and the average price target is 3.06 USD. This implies a price increase of 118.57% is expected in the next year compared to the current price of 1.4.